Literature DB >> 17591800

Aberrant methylation within RUNX3 CpG island associated with the nuclear and mitochondrial microsatellite instability in sporadic gastric cancers. Results of a GOIM (Gruppo Oncologico dell'Italia Meridionale) prospective study.

G Gargano1, D Calcara, S Corsale, V Agnese, C Intrivici, F Fulfaro, G Pantuso, M Cajozzo, V Morello, R M Tomasino, L Ottini, G Colucci, V Bazan, A Russo.   

Abstract

BACKGROUND: Gastric cancer (GC) development is a multistep process, during which numerous alterations accumulate in nuclear and mitochondrial DNA. A deficiency of repair machinery brings about an accumulation of errors introduced within simple repetitive microsatellite sequences during replication of DNA. Aberrant methylation is related to microsatellite instability (MSI) by the silencing of the hMLH1 gene. The aim of this study is to investigate a possible relationship between the RUNX3 promoter methylation, nuclear microsatellite instability (nMSI) and mitochondrial microsatellite instability (mtMSI), in order to clarify its biological role in GC. PATIENTS AND METHODS: nMSI and mtMSI were evaluated in a consecutive series of 100 GC patients. For the analysis of the nMSI, we followed the National Cancer Institute guidelines. mtMSI was assessed by analyzing a portion of the displacement-loop region. The aberrant methylation of RUNX3 was analyzed in 40 GC patients by methylation-specific PCR.
RESULTS: Overall, 55% of GC demonstrated methylation of the RUNX3 promoter; 82% of GC was classified as stable microsatellite instability, 5% as low-level microsatellite instability and 13% as high-level microsatellite instability (MSI-H); mtMSI was detected in 11% of GC. A significant association was found between mtMSI and tumor-node-metastasis staging, furthermore an interesting association between MSI-H status, mtMSI and RUNX3 methylation.
CONCLUSION: These data suggest that RUNX3 is an important target of methylation in the evolution of mtMSI and nMSI-H GC.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17591800     DOI: 10.1093/annonc/mdm236

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  7 in total

Review 1.  Genomic and epigenetic profiles of gastric cancer: potential diagnostic and therapeutic applications.

Authors:  Keishi Yamashita; Shinichi Sakuramoto; Masahiko Watanabe
Journal:  Surg Today       Date:  2010-12-30       Impact factor: 2.549

2.  Influence of Helicobacter pylori infection on the expression of MLH1 and MGMT in patients with chronic gastritis and gastric cancer.

Authors:  W Bartchewsky; M R Martini; A C Squassoni; M C Alvarez; M S P Ladeira; D M F Salvatore; M A Trevisan; J Pedrazzoli; M L Ribeiro
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-12-17       Impact factor: 3.267

Review 3.  Implication of microsatellite instability in human gastric cancers.

Authors:  Upasana Shokal; Prakash C Sharma
Journal:  Indian J Med Res       Date:  2012-05       Impact factor: 2.375

Review 4.  Association between RUNX3 promoter methylation and gastric cancer: a meta-analysis.

Authors:  Xiao-yuan Fan; Xin-lei Hu; Tie-mei Han; Na-na Wang; Yi-miao Zhu; Wen Hu; Zhen-hua Ma; Chen-jing Zhang; Xiang Xu; Zai-yuan Ye; Chun-mao Han; Wen-sheng Pan
Journal:  BMC Gastroenterol       Date:  2011-08-25       Impact factor: 3.067

5.  Mitochondrial microsatellite instability in patients with metastatic colorectal cancer.

Authors:  S Venderbosch; S van Vliet; M H C Craenmehr; F Simmer; A F J de Haan; C J A Punt; M Koopman; I D Nagtegaal
Journal:  Virchows Arch       Date:  2015-02-20       Impact factor: 4.064

6.  Runt-related Transcription Factor 3 Promoter Hypermethylation and Gastric Cancer Risk: A Meta-analysis.

Authors:  Mei Lina; Wu Changan; Zhao Qing
Journal:  Open Life Sci       Date:  2018-04-10       Impact factor: 0.938

Review 7.  Research highlights on contributions of mitochondrial DNA microsatellite instability in solid cancers - an overview.

Authors:  Abdul Aziz Mohamed Yusoff; Siti Muslihah Abd Radzak; Siti Zulaikha Nashwa Mohd Khair
Journal:  Contemp Oncol (Pozn)       Date:  2022-03-30
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.